Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives.

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery Systems
• Oncology

Background:

• Gemcitabine is a nucleoside analog deoxycytidine antimetabolite effective against various tumors.
• Rapid inactivation by deoxycytidine deaminase in vivo limits gemcitabine's therapeutic use.
• Liposomal drug delivery offers a strategy to overcome gemcitabine's limitations.

Purpose of the Study:

• To review recent strategies for improving gemcitabine's biopharmaceutical properties using liposomal devices.
• To focus on gemcitabine encapsulation in liposomes and recent advancements (last 5 years).
• To assess the potential for novel, commercializable liposomal gemcitabine formulations.

Main Methods:

• Review of scientific literature focusing on liposomal gemcitabine formulations.
• Analysis of encapsulation and complexation strategies in vesicular colloidal carriers.
• Evaluation of studies reporting enhanced pharmacological activity, plasma half-life, and tumor localization.

Main Results:

• Liposomal encapsulation enhances gemcitabine's pharmacological activity and plasma half-life.
• Improved tumor localization and reduced side effects were observed with liposomal gemcitabine.
• Recent research shows promising results for liposomal gemcitabine formulations.

Conclusions:

• Liposomal gemcitabine formulations represent a viable strategy to improve therapeutic outcomes.
• These advanced formulations offer potential for a novel, commercializable drug.
• Further development in liposomal drug delivery can enhance cancer treatment efficacy.